NeuroMetrix to Exhibit at American Diabetes Association’s 73rd Scientific Sessions

  NeuroMetrix to Exhibit at American Diabetes Association’s 73rd Scientific

                Will Feature the SENSUS Pain Management System

Business Wire

WALTHAM, Mass. -- June 10, 2013

NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the
diagnosis and treatment of the neurological complications of diabetes,
reported today that it will exhibit and participate in the American Diabetes
Association’s (ADA) 73^rd Scientific Sessions. The ADA Scientific Sessions
will be held on June 22-24 in Chicago at the McCormick Place Convention

NeuroMetrix will feature its first therapeutic product, the SENSUS^™ Pain
Management System, which was launched during the first quarter of 2013. SENSUS
is a transcutaneous electrical nerve stimulator intended for the symptomatic
relief and management of chronic intractable pain. It is the only device
designed specifically for people with diabetes and chronic pain. The most
common cause of such pain in people with diabetes is painful diabetic
neuropathy (PDN), which affects up to 5 million people in the US alone. Most
patients with PDN have moderate to severe pain and half have sleep
disturbances due to their pain. SENSUS offers physicians and their patients a
non-narcotic pain relief option as a complement to medications. The device is
lightweight, can be worn during the day, and may be used at bedtime before
going to sleep. It is activated by the press of a single button.

The Company will also conduct a meeting of its scientific advisory board
consisting of international leaders in the detection, management, and
treatment of the neurological complications of diabetes. Attendees are
encouraged to visit NeuroMetrix at booth #947.

About NeuroMetrix

NeuroMetrix is a medical device company that develops and markets home use and
point-of-care devices for the treatment of diabetic neuropathies, which affect
over 50% of people with diabetes. If left untreated, diabetic neuropathies
trigger foot ulcers that may require amputation and cause disabling chronic
pain. The annual cost of diabetic neuropathies has been estimated at $14
billion in the United States. The company markets the SENSUS^™ Pain Management
System for treating chronic pain, focusing on physicians managing patients
with painful diabetic neuropathy and similar peripheral neuropathies. The
company also markets the NC-stat^® DPNCheck^® device, which is a rapid,
accurate, and quantitative point-of-care test for diabetic neuropathy. This
product is used to detect diabetic neuropathy at an early stage and to guide
treatment. For more information, please visit


NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.